Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction. Developed by Eli Lilly as a predecessor to tirzepatide. One of the most prescribed GLP-1 agonists globally.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
A GLP-1 analog fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Type 2 diabetes
- Cardiovascular risk reduction
- Moderate weight loss
- Blood sugar regulation
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis (rare)
- Thyroid C-cell tumors (animal studies)
- Injection site reactions
- Hypoglycemia when combined with insulin
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
FDA-approved as Trulicity (2014) for type 2 diabetes and cardiovascular risk reduction (REWIND trial). Once-weekly injection via single-dose pen. One of the top-selling GLP-1 drugs globally.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.